A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Lipika Goyal(Stanford Medicine), Andrew X. Zhu(University of California San Diego), Aralee Galway(Massachusetts General Hospital), Hui Zheng(Harvard University), Kohei Shigeta(Keio University), Rebecca A. Miksad(Brigham and Women's Hospital), Avinash Kambadakone(Harvard University), Tai Hato(Harvard University), Thomas A. Abrams(Dana-Farber Cancer Institute), Michelle Knowles(Massachusetts General Hospital), Émilie Mamessier(Centre National de la Recherche Scientifique), Andrea J. Bullock(Beth Israel Deaconess Medical Center), Anthony J. Afflitto(Massachusetts General Hospital), Caroline F. Dinicola(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Eileen Regan(Dana-Farber Cancer Institute), Jill N. Allen(Harvard University), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Dan G. Duda(Harvard University), Alona Muzikansky(Johns Hopkins University)
Cited by 82
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k